PMID- 10447737
OWN - NLM
STAT- MEDLINE
DCOM- 20000404
LR  - 20190513
IS  - 0019-2805 (Print)
IS  - 1365-2567 (Electronic)
IS  - 0019-2805 (Linking)
VI  - 97
IP  - 2
DP  - 1999 Jun
TI  - Administration of interleukin-12 exerts a therapeutic instead of a long-term 
      preventive effect on mite Der p I allergen-induced animal model of airway 
      inflammation.
PG  - 232-40
AB  - Interleukin-12 (IL-12) is a key cytokine, which promotes T helper type 1 (Th1) 
      cell-mediated immunity and inhibits Th2-type responses. It has been previously 
      shown that IL-12 administration during active immunization following a single 
      allergen exposure can prevent antigen-induced increases in immunoglobulin E (IgE) 
      formation, Th2 cytokine production and bronchoalveolar lavage (BAL) eosinophils 
      in a murine model of allergic airway inflammation. Thus, these studies have now 
      been extended and two IL-12 treatment protocols on this murine model were 
      evaluated. Administration of IL-12 during the active immunization strikingly 
      increased Der p I-specific serum IgG2a and transiently decreased the levels of 
      IgG1 and IgE antibodies following multiple allergen challenges. Such early 
      treatment of IL-12 down-regulated IL-5 production and modestly up-regulated 
      interferon-gamma production but did not effect BAL eosinophilia. These results 
      suggest that repeated exposure to antigen and IL-12 is necessary to maintain a 
      persistent Th1-recall response. Furthermore, administration of IL-12 to actively 
      immunized mice, in which Th2-associated responses were established, had a 
      significant effect on IgG2a synthesis and a modest effect on IgE levels, also 
      down-regulation of IL-5 production, and markedly increased interferon-gamma 
      production and abolished recruitment of eosinophils. Therefore, these data 
      indicate that IL-12 can inhibit antigen-induced eosinophil infiltration into 
      airways, despite the existence of a Th2-associated response. Taken together, 
      these studies suggest that IL-12 may be useful as an immunotherapeutic agent in 
      the treatment of such pulmonary allergic disorders as bronchial asthma.
FAU - Lee, Y
AU  - Lee Y
AD  - Graduate Institute of Microbiology, College of Medicine, National Taiwan 
      University, Taipei, Taiwan.
FAU - Fu, C
AU  - Fu C
FAU - Chiang, B
AU  - Chiang B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Immunology
JT  - Immunology
JID - 0374672
RN  - 0 (Allergens)
RN  - 0 (Antigens, Dermatophagoides)
RN  - 0 (Glycoproteins)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Recombinant Proteins)
RN  - 187348-17-0 (Interleukin-12)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/*immunology
MH  - Animals
MH  - Antigens, Dermatophagoides
MH  - Cell Division/immunology
MH  - Female
MH  - Glycoproteins/*immunology
MH  - Immunization
MH  - Immunoglobulin E/biosynthesis
MH  - Immunoglobulin G/biosynthesis
MH  - Interleukin-12/*therapeutic use
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mites/*immunology
MH  - Recombinant Proteins/therapeutic use
MH  - Respiratory Hypersensitivity/immunology/*therapy
MH  - T-Lymphocytes/immunology
PMC - PMC2326828
EDAT- 1999/08/14 10:00
MHDA- 2001/07/04 10:01
PMCR- 2000/06/01
CRDT- 1999/08/14 10:00
PHST- 1999/08/14 10:00 [pubmed]
PHST- 2001/07/04 10:01 [medline]
PHST- 1999/08/14 10:00 [entrez]
PHST- 2000/06/01 00:00 [pmc-release]
AID - imm768 [pii]
AID - 10.1046/j.1365-2567.1999.00768.x [doi]
PST - ppublish
SO  - Immunology. 1999 Jun;97(2):232-40. doi: 10.1046/j.1365-2567.1999.00768.x.